Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

282.87 UNCHANGED
Streaming Delayed Price Updated: 1:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 612
Open 282.87
Bid (Size) 281.00 (12)
Ask (Size) 282.30 (2)
Prev. Close 282.87
Today's Range 282.87 - 282.87
52wk Range 257.80 - 346.85
Shares Outstanding N/A
Dividend Yield 3.18%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy?
Via The Motley Fool
Stock Market Hits Highs Despite Trump Tariff Threats, Nvidia, Tech Turkeys: Weekly Review
The Nasdaq isn't at a high, but it isn't far off either. 
Via Investor's Business Daily
Topics Government
Exposures Political

Performance

YTD
-4.88%
-4.88%
1 Month
-11.39%
-11.39%
3 Month
-14.41%
-14.41%
6 Month
-7.99%
-7.99%
1 Year
+3.79%
+3.79%

More News

Read More
Is Amgen Stock Still a Buy After an Unexpected Reveal of Data?
Via The Motley Fool
2 Generic Drug Stocks Ready to Surge in 2025
Via MarketBeat
Topics Government Intellectual Property
Exposures Intellectual Property Political Product Safety
Why Amgen's Weight Loss Result Is a Win for Eli Lilly
Via The Motley Fool
Decoding Amgen's Options Activity: What's the Big Picture?
Via Benzinga
Amgen's Options Frenzy: What You Need to Know
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Stocks Mixed Ahead Of Fed Minutes, Mexican Peso Tumbles To Over 2-Year Lows On Tariffs Fears: What's Driving Markets Tuesday?
Via Benzinga
Topics Economy
Exposures Interest Rates
Biden Proposes Medicare, Medicaid Access For Popular Weight-Loss Drugs
Via Benzinga
What Analysts Are Saying About Amgen Stock
Via Benzinga
Pain In Retail
Via Talk Markets
Topics Stocks / Equities
Amgen Crashes 12% After Weight-Loss Drug Meets Eli Lilly's In A Key Test
Via Investor's Business Daily
Amgen Reveals Data From Closely Watched Monthly Obesity Drug, With Weight Loss Of Up To 20% At One Year And No Plateau
Via Benzinga
Investing in Pharma Stocks? Check These 3 Things First
Via The Motley Fool
Weight-Loss Drugs Don't Seem To Impress RFK Jr. Should Eli Lilly, Novo Nordisk Investors Worry?
Via Investor's Business Daily
Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs
Via Benzinga
Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst
Via Benzinga
Neurogene, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Dow Tumbles Over 300 Points Following Economic Reports, Nvidia, Microsoft Decline: Fear & Greed Index Moves To 'Neutral' Zone
Via Benzinga
Topics Stocks
Exposures US Equities
2 Reasons to Buy Amgen Stock, and 1 Reason to Be Cautious
Via The Motley Fool
AMGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Amgen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Want Decades of Passive Income? Buy This Index Fund and Hold It Forever
Via The Motley Fool
2 Dividend Stocks to Buy Hand Over Fist in November
Via The Motley Fool
Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.